Merck (MRK) Depreciation & Amortization (CF) (2009 - 2026)

Merck (MRK) has 18 years of Depreciation & Amortization (CF) data on file, last reported at $581.0 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $581.0 million, up 15.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 billion (up 115.87% YoY), and the FY2025 annual result was $3.0 billion, up 45.0% from the prior year.
• Depreciation & Amortization (CF) retreated to $581.0 million in Q1 2026 per MRK's latest filing, from $1.5 billion in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1.5 billion in Q4 2025 and troughed at $1.0 million in Q3 2025.
• A 5-year average of $451.2 million and a median of $448.0 million in 2022 frame the typical range for Depreciation & Amortization (CF).
• On a YoY basis, Depreciation & Amortization (CF) climbed as much as 579.1% in 2025 and fell as far as 98.82% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $430.0 million in 2022, then climbed by 16.74% to $502.0 million in 2023, then grew by 3.19% to $518.0 million in 2024, then soared by 188.22% to $1.5 billion in 2025, then sank by 61.09% to $581.0 million in 2026.
• Business Quant data shows MRK's Depreciation & Amortization (CF) at $581.0 million in Q1 2026, $1.5 billion in Q4 2025, and $1.0 million in Q3 2025.